-Deccan Chronicle Prime Minister Narendra Modi may be patting himself on the back because President Barack Obama has agreed to India's position on food stockholding norms in World Trade Organisation (WTO). However, New Delhi seems to be bending over backwards to accommodate the American government and giant multinational corporations (MNCs) in the pharmaceutical industry, which will work to the detriment of our country's interests. In less than six months, the Modi government...

-The Hindu   No one can attack India's well-founded Intellectual Property regime as being weak merely because a drug that is claimed to be an invention fails the test of law India and its intellectual property (IP) laws have been the subject of sharp criticism recently. Now, there is talk of the government invoking emergency provisions with regard to Dasatinib, a cancer drug. The decibel level may go up several notches. Let us look...

-The Hindu Differences over intellectual property rights (IPRs) have emerged as a strong undercurrent in India's economic relations with the U.S. The attempt by the influential pharmaceutical lobby to stymie India's efforts to ensure the supply of medicines at affordable rates without violating existing treaty commitments, requires a principled response from New Delhi. At the core of the issue is what Columbia University Professor Arvind Panagariya calls "the hijacking of...

-The Business Standard The recent US-India friction over trade is being driven by Big Pharma Apart from the deterioration of the business environment generally, which impacts both domestic and foreign investors, retrospective taxation has figured most prominently in the media as the principal cause of growing scepticism among foreign investors. Entirely missing from the discourse has been an equally potent factor with wholly foreign origins: the hijacking of the economic policy...

-The Hindu Chennai: With U.S Trade Representative Michael Froman set to announce a trade enforcement action tied to India, the highly influential U.S Chamber of Commerce has lashed out at India's recent pattern of pharma patent denials, pointing out that the country's actions "are not about access to medicine." In the case of Swiss drug-maker Novartis, whose cancer drug's patent protections were dismissed by the Supreme Court, the chamber has argued that...